Aurinia Pharmaceuticals Inc (AUP)

Healthcare Pharmaceuticals & Medical Research Biotechnology & Medical Research

Track Share on 𝕏

Stock chart
Ticker: AUP Exchange: TOR


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale
Past 90 days
 
Value bought
 
Value sold
 
Net insiders buying
 
Trades (buy and sell)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Total value Details
2024-03-07 2024-03-06 S Sale

Habig Scott Michael

Chief Commercial Officer

Officer
17,777 -3.6%
5.60
99,551 USD 		17,777 -3.6% 5.60 99,551 USD
2024-03-07 2024-03-06 S Sale

Greenleaf Peter

Chief Executive Officer

Executive Director
126,981 -7.7%
5.60
711,094 USD 		126,981 -7.7% 5.60 711,094 USD
2024-03-07 2024-03-06 S Sale

Miller Joseph M

Chief Financial Officer

Officer
34,811 -6.6%
5.60
194,942 USD 		34,811 -6.6% 5.60 194,942 USD
2024-03-07 2024-03-06 S Sale

Robertson Stephen P.

EVP, General Counsel

Officer
57,745 -11.5%
5.60
323,372 USD 		57,745 -11.5% 5.60 323,372 USD
2024-03-07 2024-03-06 S Sale

Donley Matthew Maxwell

EVP, Ops & Strategy

Officer
40,665 -6.5%
5.51
224,064 USD 		40,665 -6.5% 5.51 224,064 USD
2024-02-29 2024-02-27 S Sale

Knappertz Volker

EVP, Research and Development

Officer
4,930 -1.5%
6.10
30,073 USD 		4,930 -1.5% 6.10 30,073 USD
2024-02-29 2024-02-27 PS Planned sale

Knappertz, Volker

Senior Officer of Issuer

Officer
4,930 -16.0%
6.10
30,073 USD 		4,930 -16.0% 6.10 30,073 USD
2024-02-26 2024-02-20 PP Planned purchase

Donley, Matthew

Senior Officer of Issuer

Officer
4,930 +7.9%
4,930.00
24,304,900 CAD 		4,930 +7.9% 4,930.00 24,304,900 CAD
2024-02-22 2024-02-20 S Sale

Habig Scott Michael

Chief Commercial Officer

Officer
15,867 -3.1%
5.48
86,951 USD 		15,867 -3.1% 5.48 86,951 USD
2024-02-22 2024-02-20 S Sale

Knappertz Volker

EVP, Research and Development

Officer
25,146 -7.2%
5.48
137,800 USD 		25,146 -7.2% 5.48 137,800 USD
2023-05-23 2023-05-23 S Sale

Leversage Jill

Non-Executive Director
4,815 -20.6%
11.26
54,217 USD 		4,815 -20.6% 11.26 54,217 USD
2023-05-23 2023-05-23 S Sale

Jayne David R.W.

Non-Executive Director
8,733 -15.0%
11.26
98,334 USD 		8,733 -15.0% 11.26 98,334 USD
2023-05-23 2023-05-23 S Sale

MacKay-Dunn R. Hector

Non-Executive Director
4,818 -16.6%
11.26
54,251 USD 		4,818 -16.6% 11.26 54,251 USD
2023-05-23 2023-05-23 S Sale

Billen Daniel

Non-Executive Director
4,650 -12.2%
11.26
52,359 USD 		4,650 -12.2% 11.26 52,359 USD
2023-05-23 2023-05-19 S Sale

Hagan Joseph P

Non-Executive Director
272 -2.2%
10.58
2,878 USD 		272 -2.2% 10.58 2,878 USD
2023-03-06 2023-03-02 S Sale

Robertson Stephen P.

EVP, General Counsel

Officer
19,402 -6.0%
8.94
173,454 USD 		19,402 -6.0% 8.94 173,454 USD
2023-03-06 2023-03-02 S Sale

Greenleaf Peter

Chief Executive Officer

Executive Director
32,750 -3.2%
8.94
292,785 USD 		32,750 -3.2% 8.94 292,785 USD
2023-03-06 2023-03-02 B Purchase

MILNE GEORGE M JR

Non-Executive Director
20,000 +40.0%
8.91
178,284 USD 		20,000 +40.0% 8.91 178,284 USD
2023-03-06 2023-03-02 S Sale

Miller Joseph M

Chief Financial Officer

Officer
11,296 -3.3%
8.94
100,986 USD 		11,296 -3.3% 8.94 100,986 USD
2022-11-23 2022-11-21 PP Planned purchase

Donley Matthew Maxwell

Ex VP, Internal Operations

Officer
10,000 +55.8%
4.66
46,600 USD 		10,000 +55.8% 4.66 46,600 USD
2022-11-14 2022-11-09 B Purchase

Habig Scott Michael

Chief Commercial Officer

Officer
5,000 +inf%
5.02
25,075 USD 		5,000 +inf% 5.02 25,075 USD
2022-11-09 2022-11-07 B Purchase

Martin Michael Robert

Chief Business Officer

Officer
30,000 +50.4%
5.16
154,800 USD 		30,000 +50.4% 5.16 154,800 USD
2022-03-11 2022-03-09 B Purchase

MacKay-Dunn R. Hector

Non-Executive Director
5,000 +83.3%
11.00
54,985 USD 		5,000 +83.3% 11.00 54,985 USD
2022-03-08 2022-03-04 B Purchase

MILNE GEORGE M JR

Non-Executive Director
5,000 +11.1%
10.82
54,100 USD 		5,000 +11.1% 10.82 54,100 USD
2022-03-04 2022-03-02 S Sale

Donley Matthew Maxwell

Ex VP, Intern'l Operations

Officer
3,052 -15.8%
12.01
36,655 USD 		3,052 -15.8% 12.01 36,655 USD
2022-03-04 2022-03-02 S Sale

Colao Massimilano

Chief Commercial Officer

Officer
3,205 -19.2%
12.01
38,492 USD 		3,205 -19.2% 12.01 38,492 USD
2022-03-04 2022-03-02 S Sale

Greenleaf Peter

Chief Executive Officer

Executive Director
9,068 -21.6%
12.01
108,907 USD 		9,068 -21.6% 12.01 108,907 USD
2022-03-04 2022-03-02 S Sale

Miller Joseph M

Chief Financial Officer

Officer
3,060 -31.6%
12.01
36,751 USD 		3,060 -31.6% 12.01 36,751 USD
2022-03-04 2022-03-02 S Sale

Huizinga Robert Bindert

EVP of Research

Officer
4,849 -6.5%
12.01
58,236 USD 		4,849 -6.5% 12.01 58,236 USD
2022-03-04 2022-03-02 S Sale

Martin Michael Robert

Chief Business Officer

Officer
4,849 -7.5%
12.01
58,236 USD 		4,849 -7.5% 12.01 58,236 USD
2022-03-04 2022-03-02 S Sale

Solomons Neil

Chief Medical Officer

Officer
4,846 -5.1%
12.01
58,200 USD 		4,846 -5.1% 12.01 58,200 USD
2022-01-04 2022-01-03 PS Planned sale

Hagan Joseph P

Non-Executive Director
634 -15.3%
23.29
14,766 USD 		634 -15.3% 23.29 14,766 USD
2022-01-04 2022-01-03 PS Planned sale

Hagan Joseph P

Non-Executive Director
39,366 -90.5%
22.58
888,884 USD 		39,366 -90.5% 22.58 888,884 USD
2021-12-15 2021-12-13 B Purchase

Leversage Jill

Non-Executive Director
1,600 +43.2%
20.04
32,064 USD 		1,600 +43.2% 20.04 32,064 USD
2021-11-12 2021-11-11 PS Planned sale

Solomons Neil

Chief Medical Officer

Officer
100,000 -53.4%
28.89
2,889,000 USD 		100,000 -53.4% 28.89 2,889,000 USD
2021-11-12 2021-11-11 PS Planned sale

Martin Michael Robert

Chief Business Officer

Officer
11,000 -16.5%
29.50
324,500 USD 		11,000 -16.5% 29.50 324,500 USD
2021-11-12 2021-11-11 PS Planned sale

Martin Michael Robert

Chief Business Officer

Officer
29,000 -30.3%
28.82
835,780 USD 		29,000 -30.3% 28.82 835,780 USD
2021-11-12 2021-11-10 PS Planned sale

Solomons Neil

Chief Medical Officer

Officer
10,000 -10.3%
30.55
305,500 USD 		10,000 -10.3% 30.55 305,500 USD
2021-11-12 2021-11-10 PS Planned sale

Solomons Neil

Chief Medical Officer

Officer
90,000 -48.1%
31.17
2,805,300 USD 		90,000 -48.1% 31.17 2,805,300 USD
2021-11-12 2021-11-10 PS Planned sale

Martin Michael Robert

Chief Business Officer

Officer
10,000 -13.0%
30.55
305,500 USD 		10,000 -13.0% 30.55 305,500 USD
2021-11-12 2021-11-10 PS Planned sale

Martin Michael Robert

Chief Business Officer

Officer
50,000 -39.4%
31.26
1,563,000 USD 		50,000 -39.4% 31.26 1,563,000 USD
2021-11-12 2021-11-09 PS Planned sale

Solomons Neil

Chief Medical Officer

Officer
50,000 -36.4%
30.17
1,508,500 USD 		50,000 -36.4% 30.17 1,508,500 USD
2021-11-12 2021-11-09 PS Planned sale

Martin Michael Robert

Chief Business Officer

Officer
50,000 -28.3%
30.17
1,508,500 USD 		50,000 -28.3% 30.17 1,508,500 USD
2021-11-03 2021-11-01 PS Planned sale

Solomons Neil

Chief Medical Officer

Officer
45,000 -24.7%
31.64
1,423,800 USD 		45,000 -24.7% 31.64 1,423,800 USD
2021-11-03 2021-11-01 PS Planned sale

Martin Michael Robert

Chief Business Officer

Officer
45,000 -20.3%
31.64
1,423,800 USD 		45,000 -20.3% 31.64 1,423,800 USD
2021-10-26 2021-10-25 PS Planned sale

Huizinga Robert Bindert

EVP of Research

Officer
130,000 -66.4%
29.75
3,867,500 USD 		130,000 -66.4% 29.75 3,867,500 USD
2021-09-14 2021-09-14 PS Planned sale

Martin Michael Robert

Chief Business Officer

Officer
90,000 -33.7%
21.19
1,907,217 USD 		90,000 -33.7% 21.19 1,907,217 USD
2021-09-14 2021-09-14 PS Planned sale

Huizinga Robert Bindert

EVP of Research

Officer
22,500 -17.5%
21.75
489,375 USD 		22,500 -17.5% 21.75 489,375 USD
2021-09-14 2021-09-10 PS Planned sale

Martin Michael Robert

Chief Business Officer

Officer
25,000 -12.4%
19.80
495,000 USD 		25,000 -12.4% 19.80 495,000 USD
2021-09-14 2021-09-10 PS Planned sale

Solomons Neil

Chief Medical Officer

Officer
150,000 -52.2%
19.84
2,976,000 USD 		150,000 -52.2% 19.84 2,976,000 USD
2021-09-14 2021-09-10 PS Planned sale

Huizinga Robert Bindert

EVP of Research

Officer
5,000 -3.7%
19.76
98,800 USD 		5,000 -3.7% 19.76 98,800 USD
2021-09-14 2021-09-10 PS Planned sale

Huizinga Robert Bindert

EVP of Research

Officer
5,000 -3.6%
19.83
99,150 USD 		5,000 -3.6% 19.83 99,150 USD
2021-06-23 2021-06-22 PS Planned sale

Martin Michael Robert

Chief Business Officer

Officer
5,000 -2.3%
13.76
68,800 USD 		5,000 -2.3% 13.76 68,800 USD
2021-05-13 2021-05-12 B Purchase

MacKay-Dunn R. Hector

Non-Executive Director
1,600 +36.4%
11.28
18,040 USD 		1,600 +36.4% 11.28 18,040 USD
2021-05-13 2021-05-12 B Purchase

MacKay-Dunn R. Hector

Non-Executive Director
1,400 +46.7%
11.26
15,764 USD 		1,400 +46.7% 11.26 15,764 USD
2021-05-13 2021-05-11 B Purchase

MacKay-Dunn R. Hector

Non-Executive Director
1,000 +50.0%
11.14
11,140 USD 		1,000 +50.0% 11.14 11,140 USD
2021-05-13 2021-05-11 B Purchase

MacKay-Dunn R. Hector

Non-Executive Director
500 +33.3%
11.17
5,585 USD 		500 +33.3% 11.17 5,585 USD
2021-05-12 2021-05-11 B Purchase

Donley Matthew Maxwell

Ex VP, Intern'l Operations

Officer
9,900 +inf%
10.07
99,739 USD 		9,900 +inf% 10.07 99,739 USD
2021-05-11 2021-05-11 B Purchase

Miller Joseph M

Chief Financial Officer

Officer
1,000 +inf%
9.74
9,740 USD 		1,000 +inf% 9.74 9,740 USD
2021-03-15 2021-03-12 S Sale

Solomons Neil

Chief Medical Officer

Officer
40,000 -17.6%
13.49
539,600 USD 		40,000 -17.6% 13.49 539,600 USD
2021-03-09 2021-03-05 B Purchase

MILNE GEORGE M JR

Non-Executive Director
5,000 +12.5%
13.00
65,000 USD 		5,000 +12.5% 13.00 65,000 USD
2021-02-02 2021-01-29 B Purchase

Leversage Jill

Non-Executive Director
1,200 +inf%
16.03
19,236 USD 		1,200 +inf% 16.03 19,236 USD
2021-02-02 2021-01-29 B Purchase

Leversage Jill

Non-Executive Director
400 +inf%
16.03
6,412 USD 		400 +inf% 16.03 6,412 USD
2021-01-29 2021-01-28 B Purchase

Robertson Stephen P.

EVP, General Counsel

Officer
900 +49.5%
16.14
14,526 USD 		900 +49.5% 16.14 14,526 USD